Recommendation of patient selection for molecular-targeted agents in RAI-refractory locally advanced or metastatic differentiated thyroid carcinoma

DOI Web Site
  • Ito Ken-ichi
    Committee of pharmacological therapy for thyroid cancer Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine
  • Shimizu Kazuo
    Committee of pharmacological therapy for thyroid cancer Department of Surgery, Kanaji Hospital
  • Yoshida Akira
    Committee of pharmacological therapy for thyroid cancer Department of Breast and Endocrine Surgery, Kanagawa Cancer Center
  • Suzuki Shinichi
    Committee of pharmacological therapy for thyroid cancer Department of Thyroid and Endocrinology, Fukushima Medical University Hospital
  • Imai Tsuneo
    Committee of pharmacological therapy for thyroid cancer Division of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University
  • Okamoto Takahiro
    Committee of pharmacological therapy for thyroid cancer Department of Endocrine Surgery, Tokyo Women̓ s Medical University
  • Hara Naoto
    Committee of pharmacological therapy for thyroid cancer Department of Breast-Thyroid-Endocrine Surgery, Institute of Clinical Medicine, University of Tsukuba
  • Tsutsui Hidemitsu
    Committee of pharmacological therapy for thyroid cancer Department of Thoracic and Thyroid Surgery, Tokyo Medical University Hospital
  • Sugitani Iwao
    Committee of pharmacological therapy for thyroid cancer Division of Endocrine Surgery, Department of Surgery, Nippon Medical School
  • Sugino Kiminori
    Committee of pharmacological therapy for thyroid cancer Department of Surgery, Ito Hospital
  • Kinuya Seigo
    Japanese Society of Nuclear Medicine Department of Nuclear Medicine, Division of Nuclear Medicine Services, Kanazawa University Hospital
  • Nakada Kunihiro
    Japanese Society of Nuclear Medicine Department of Radiology Hokko Memorial Hospital
  • Higashi Tatsuya
    Japanese Society of Nuclear Medicine Shiga Medical Center Research Institute
  • Noguchi Yasushi
    Japanese Society of Nuclear Medicine Department of Radiology, Noguchi Thyroid Clinic and Hospital Foundation
  • Abe Koichiro
    Japanese Society of Nuclear Medicine Department of Diagnostic imaging & Nuclear Medicine, Tokyo Women̓ s Medical University
  • Uchiyama Mayuki
    Japanese Society of Nuclear Medicine Department of Radiology, Jikei University School of Medicine
  • Shiga Toru
    Japanese Society of Nuclear Medicine Department of Nuclear Medicine, Hokkaido University

Bibliographic Information

Other Title
  • 放射性ヨウ素治療抵抗性の局所進行性，再発・転移性分化型甲状腺癌に対する分子標的薬治療の適応患者選択の指針
  • ホウシャセイ ヨウソ チリョウ テイコウセイ ノ キョクショ シンコウセイ,サイハツ ・ テンイ ショウブンカガタ コウジョウセンガン ニ タイスル ブンシ ヒョウテキヤク チリョウ ノ テキオウ カンジャ センタク ノ シシン

Search this article

Abstract

本邦においても進行甲状腺癌に対する分子標的薬が承認され，放射性ヨウ素治療（RAI）抵抗性進行性分化型甲状腺癌に対する治療が新しい時代に入った。しかし，適応患者の選択に際しては，病理組織型，進行再発後の放射性ヨウ素（RAI）治療に対する反応などを適切に評価した上で判断することが重要であり，分子標的薬特有の有害事象に対する注意も必要である。分子標的薬の適正使用に際しては治療による恩恵と有害事象を十分に考慮した適応患者の選択が肝要である。また，未解決の問題に関しては，本邦での臨床試験による検討が必要と考えられる。

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top